Total Funding
77
56
Total FundingVenture - Series Unknown raised
Growth Score
11 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
49651
MaxCyte specializes in cell modification technologies that enable the discovery, development, and manufacture of various classes.
- Rekha Hemrajani: Board Member, Chair of Compensation CommitteePast Role: Rapt Therapeutics, Chief Operating Officer
Tom Ross: Executive Vice President - Global SalesPast Role: CapForce, Senior Vice President - Commerical Operations
About the Company
MaxCyte specializes in cell modification technologies that enable the discovery, development, and manufacture of various classes of therapeutics for a range of chronic and acute diseases. It provides MaxCyte STX, a scalable transfection system for the scalable and reagent-free (co) transfection of primary cells, stem cells, and cell lines involved
in the areas of cell-based assays for content screening, preclinical protein production, and small molecule.
